Benzinga · Aug 28, 2026
TD Cowen Maintains Buy on Medtronic, Raises Price Target to $110
TD Cowen analyst Joshua Jennings maintains Medtronic (NYSE:MDT) with a Buy and raises the price target from $100 to $110.
NYSE · MDT
Medtronic plc
Healthcare · Medical - Devices
$91.23
Up+$1.26 (+1.40%)
Updated Aug 30, 2026, 5:16 AM
SID Score
6.8/10
Composite research score
Smart Money
38/100
Bearish
- Market cap
- 127.94B
- P/E ratio
- 26.83
- Dividend yield
- 3.87%
- 52-week range
- $73.31 – $105.50
- Volume
- 6.47M
- Avg. volume
- 7.16M
Price performance
MDT price history
1M range · 20 trading sessions · Daily adjusted prices
MDT closed at $91.23 after 20 trading sessions, up 5.25% for the selected period.
- Last close
- $91.23
- Period change
- +5.25%
- Period low
- $85.92
- Period high
- $94.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $90.29 | $91.56 | $89.94 | $91.23 | 6.47M |
| Aug 27, 2026 | $91.50 | $91.61 | $89.96 | $89.97 | 7.77M |
| Aug 26, 2026 | $91.08 | $92.53 | $90.75 | $92.02 | 6.05M |
| Aug 25, 2026 | $92.275 | $92.82 | $91.11 | $91.14 | 6.8M |
| Aug 24, 2026 | $93.43 | $94.05 | $92.655 | $92.90 | 6.01M |
| Aug 21, 2026 | $92.57 | $93.55 | $91.73 | $93.35 | 7.49M |
| Aug 20, 2026 | $93.37 | $94.53 | $92.23 | $92.30 | 6.35M |
| Aug 19, 2026 | $92.38 | $94.715 | $91.95 | $94.13 | 5.64M |
| Aug 18, 2026 | $92.00 | $93.09 | $91.4652 | $92.09 | 6.79M |
| Aug 17, 2026 | $90.89 | $91.79 | $90.0827 | $90.60 | 7.83M |
| Aug 14, 2026 | $90.99 | $91.99 | $90.41 | $91.27 | 8.25M |
| Aug 13, 2026 | $91.44 | $91.61 | $90.4125 | $90.58 | 6.48M |
| Aug 12, 2026 | $88.96 | $91.03 | $88.50 | $90.76 | 6.23M |
| Aug 11, 2026 | $89.26 | $90.73 | $88.70 | $90.68 | 8.39M |
| Aug 10, 2026 | $87.16 | $89.45 | $86.715 | $89.41 | 6.57M |
| Aug 7, 2026 | $85.46 | $87.19 | $84.955 | $87.16 | 5.06M |
| Aug 6, 2026 | $87.01 | $87.30 | $85.675 | $85.92 | 4.98M |
| Aug 5, 2026 | $86.50 | $86.8258 | $85.01 | $85.99 | 4.73M |
| Aug 4, 2026 | $85.49 | $86.24 | $84.95 | $86.20 | 6.36M |
| Aug 3, 2026 | $86.81 | $87.89 | $85.81 | $86.68 | 6.79M |
Latest MDT news
The latest Smart Investors Daily articles mentioning MDT.
Stock researchCompany · Overview
MDT research
Overview
Company profile and research snapshot.
Company profile
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $111.50
- Implied upside
- —
- Analysts
- 21
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2026 | TD Cowen | Buy | — |
| Aug 27, 2026 | Needham | Buy | — |
| Aug 18, 2026 | BTIG | Buy | — |
| Jul 28, 2026 | UBS | Buy | — |
| Jul 10, 2026 | TD Cowen | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 28, 2026
Medtronic Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Medtronic plc (NYSE: MDT) will release Q1 earnings on Sept. 1. Analysts predict $1.39 EPS and $9.54B revenue. Stock fell 2.2% to $89.97 on Aug. 27.
Benzinga · Aug 27, 2026
Needham Maintains Buy on Medtronic, Raises Price Target to $114
Needham analyst Mike Matson maintains Medtronic (NYSE:MDT) with a Buy and raises the price target from $101 to $114.
SeekingAlpha · Aug 21, 2026
Medtronic: The CAS Catalyst Can Close A 27% Peer Discount
Medtronic (MDT) stock rated Buy: CAS growth upside, discounted valuation, 3.1% yield, and key guidance variables. Read here for more analysis.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
